Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.21 USD | +0.55% | -1.39% | -17.91% |
Sales 2024 * | 50M 4.17B | Sales 2025 * | 71.15M 5.93B | Capitalization | 250M 20.81B |
---|---|---|---|---|---|
Net income 2024 * | 5M 417M | Net income 2025 * | 26M 2.17B | EV / Sales 2024 * | 4.99 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.51 x |
P/E ratio 2024 * |
44.2
x | P/E ratio 2025 * |
9.89
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.71% |
Latest transcript on Fennec Pharmaceuticals Inc.
1 day | +0.55% | ||
1 week | -1.39% | ||
Current month | -17.18% | ||
1 month | -15.43% | ||
3 months | -6.97% | ||
6 months | +32.90% | ||
Current year | -17.91% |
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07/09/07 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25/11/25 |
Khalid Islam
CHM | Chairman | 67 | 25/14/25 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 9.21 | +0.55% | 154,291 |
25/24/25 | 9.16 | +0.99% | 120,030 |
24/24/24 | 9.07 | -1.84% | 182,107 |
23/24/23 | 9.24 | -1.49% | 288,706 |
22/24/22 | 9.38 | +0.43% | 165,455 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.91% | 250M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FENC Stock